LAURUS's Complete FDA Record

FDA action counts

Risk pattern analysis

Argus HQ analysis — not an FDA finding

This section is Argus HQ analysis, not an FDA finding. LAURUS has 1 FDA event on file. A pattern across multiple FDA touchpoints does not by itself establish that any specific product currently poses a risk; it reflects only the frequency of FDA engagement with this company as recorded in Argus HQ's database. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ does not independently verify FDA's underlying findings; this page summarizes what FDA has published and links back to the original FDA source for each event. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.

Enforcement history

On 2026-07-10, Argus HQ recorded an FDA approval for LAURUS, rated "info" severity in Argus HQ's classification: LAURUS — ANDA approval: RILPIVIRINE HYDROCHLORIDE (unspecified). Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed.

Frequently asked questions

What is the most recent FDA action against LAURUS?

The most recent FDA event Argus HQ has on file for LAURUS is dated 2026-07-10, with a severity rating of "info" in Argus HQ's classification. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.

Does Argus HQ track new FDA actions for LAURUS automatically?

Yes. Argus HQ ingests FDA sources daily, including FDA warning letters, recalls, drug and biologic approvals, and Form 483 inspection observations. When a new FDA action linked to LAURUS is observed, this page's event count and history update automatically.

How many FDA actions does Argus HQ track for LAURUS?

1 total: 0 warning letters, 0 recalls, 1 approval record, and 0 Form 483 inspection citations.

What is the most recent FDA action on file for LAURUS?

July 10, 2026. Argus HQ ingests new FDA enforcement records daily.

Related enforcement actions

• LAURUS — ANDA approval: RILPIVIRINE HYDROCHLORIDE (unspecified) →

Compare with

• LAURUS vs Medline Industries, LP
• LAURUS vs ARROW INTERNATIONAL, LLC
• LAURUS vs Stryker Sustainability Solutions
• LAURUS vs Philips North America
• LAURUS vs Guardian Drug Co. Inc.